Biotech stocks are surging. How investors can play the new drug innovation boom

Biotech stocks are rallying as clinical wins, M&A and new drug technologies revive the sector. Here are the ETFs and stocks analysts favor.

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.